{"id":"envafolimab-with-new-manufacturing-process","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05849311"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"Envafolimab with new manufacturing process","companyId":"3d-medicines-sichuan-co-ltd","mechanism":{"target":"PD-L1","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Envafolimab is a humanized single-domain antibody fragment that binds to programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 receptors on T-cells. This blockade restores anti-tumor immune responses by removing inhibitory signals that tumors use to evade immune surveillance.","oneSentence":"Envafolimab blocks PD-L1 to restore T-cell activity against tumor cells.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123489,"model":"claude-sonnet-4-5-20250929"},"companyName":"3D Medicines (Sichuan) Co., Ltd.","competitors":[{"name":"Pembrolizumab","brand":"Keytruda","company":"Merck","rationale":"PD-1 inhibitor approved for multiple solid tumors"},{"name":"Atezolizumab","brand":"Tecentriq","company":"Roche","rationale":"PD-L1 inhibitor for various cancers"},{"name":"Durvalumab","brand":"Imfinzi","company":"AstraZeneca","rationale":"PD-L1 inhibitor competing in similar indications"}],"description":"Envafolimab with a new manufacturing process is an investigational PD-L1 inhibitor being developed by 3D Medicines. It represents a reformulated version of the subcutaneously administered anti-PD-L1 antibody, currently in Phase 1 clinical development to evaluate the new production method.","genericName":"Envafolimab with new manufacturing process","indications":{"approved":[{"status":"investigational","condition":"Solid tumors","patientPopulation":"Adult patients, investigational"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}